The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.
Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential
Open accessAbstract
Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite that enhances both platelet responsiveness and in vivo thrombosis potential in animal models, and TMAO plasma levels predict incident atherothrombotic event risks in human clinical studies. TMAO is formed by gut microbe-dependent metabolism of trimethylamine (TMA) moiety-containing nutrients, which are abundant in a Western diet. Here, using a mechanism-based inhibitor approach targeting a major microbial TMA-generating enzyme pair, CutC and CutD (CutC/D), we developed inhibitors that are potent, time-dependent, and irreversible and that do not affect commensal viability. In animal models, a single oral dose of a CutC/D inhibitor significantly reduced plasma TMAO levels for up to 3 d and rescued diet-induced enhanced platelet responsiveness and thrombus formation, without observable toxicity or increased bleeding risk. The inhibitor selectively accumulated within intestinal microbes to millimolar levels, a concentration over 1-million-fold higher than needed for a therapeutic effect. These studies reveal that mechanism-based inhibition of gut microbial TMA and TMAO production reduces thrombosis potential, a critical adverse complication in heart disease. They also offer a generalizable approach for the selective nonlethal targeting of gut microbial enzymes linked to host disease limiting systemic exposure of the inhibitor in the host.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
62 Own result · 23 Not checked yet · 12 Own interpretation · 3 Own method · 2 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Addition of FMC at increasing concentrations lowered maximal enzyme velocity (Vmax) with no apparent effect on substrate affinity (KM) (Supplementary Figure 5), indicating that FMC acts kinetically as a non-competitive inhibitor.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The choline diet elicited no differences in multiple indices of platelet activation, including surface phosphatidylserine content (p=0.84) in ADP-stimulated washed platelets or levels of von Willebrand factor (p=0.14), alpha granule release (p=0.31), or prothrombotic microvesicle release (p=0.66) in platelet-rich plasma (PRP) in the absence of agonist”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IMC displayed an in vitro potency (IC50) approximately 10,000 times greater than DMB against the recombinant P. mirabilis CutC/D lysate, recombinant D. alaskensis CutC/D lysate, and wild-type, whole-cell P. mirabilis in culture”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“DMB was directly incubated with the PRP preparations, and no effects on the platelet aggregometry responses either alone, or in the presence of agonist (ADP), were observed”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Choline supplementation resulted in marked TMAO elevation and shortening of vessel occlusion time (p<0.0001) as previously reported15”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
What the sources say
- Not checked yetcites [15] Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111–124 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“both IMC and FMC demonstrated enhanced inhibitory potency following longer pre-incubation times with the enzyme prior to the addition of d9-choline substrate”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No signs of toxicity were observed in mice following chronic exposure to wholly effective doses of FMC (10 mg/kg) or IMC (100 mg/kg)”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Modest but relatively equal amounts of FMC and FMB (Supplementary Figure 9) and IMC and IMB (Supplementary Figure 10) were observed in urine.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“following single or chronic dosing with FMC or IMC, no changes were noted in plasma levels for homocysteine, dimethylglycine, or folate pathway-related metabolites (all p>0.05, data not shown).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These same trends for TMA and TMAO were observed in the urine and feces following administration of either FMC or IMC”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 9
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Screening of IMC and FMC in a battery of pharmacological safety tests failed to show: (i) inhibition in hERG channel function; (ii) toxicity to mitochondria in HepG2 cells cultured in glucose- or galactose-supplemented media; (iii) adverse effects on the viability of HK-2 cells in culture; or (iv) adverse signals during AMES testing at levels up to 1000 μg/well”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both FMC and IMC induced an almost complete reduction in plasma TMA and TMAO levels following a single oral dose (via gavage) for a sustained period, with FMC demonstrating a striking trough that persisted for over 3 days (Figure 3b right), and IMC for over 2 days post-gavage”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“reversible inhibition of CutC/D activity following dialysis was observed with an alternative, potent inhibitor developed, phenylcholine (IC50=150 nM against P. mirabilis CutC/D)”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the fluorinated choline analogue, fluoromethylcholine (FMC), was the most potent halomethylcholine examined (IC50=900 pM against P. mirabilis CutC/D), and in docking calculations, was predicted to have the tightest interaction with the active site”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increasing concentrations of IMC similarly decreased Vmax, but also increased KM (Supplementary Figure 5), indicating IMC acts kinetically as a mixed mechanism inhibitor, with elements of both competitive and non-competitive inhibition.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“despite the high dose of DMB provided, choline diet-associated TMAO elevations, increased platelet aggregation, and shortened in vivo thrombus formation were not fully rescued compared to chow-fed mice”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the halomethylbetaines were found to act as CutC/D TMA lyase inhibitors but approximately 2–3 orders of magnitude weaker than their choline counterparts”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FMC and IMC were directly incubated with PRP from both mice and humans (with or without agonist), and no effects on platelet aggregometry responses were observed. Their primary in vivo metabolites, FMB and IMB, also did not affect platelet aggregometry responses in human PRP”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of gut microbial choline TMA lyase activity suppresses choline diet-enhanced platelet aggregation and in vivo rate of thrombus formation without increased bleeding time
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In alternative studies in both male and female mice with more prolonged exposures (15–20 weeks) to IMC, no adverse effects were observed, including normal indices of renal function, liver function, and CBC with differential”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“analyses of feces revealed the majority of FMC and IMC remain in the gut luminal compartment, with only nominal levels of FMB or IMB present in fecal samples”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“choline supplementation resulted in 10-fold higher plasma TMAO levels (p<0.0001) and enhanced aggregometry response to submaximal levels of ADP (1 μM) in PRP (p<0.0001; Figure 1a).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“both FMC and IMC demonstrated remarkable capacity to suppress production of d9-TMA (EC50=0.008 and 0.5 mg/kg, respectively; Supplementary Figure 8) and d9-TMAO (EC50=0.01 mg/kg and 0.2 mg/kg, respectively; Table 1, Figure 3a right).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the TMAO enhancing effect on stimulus-dependent platelet aggregation was also observed with washed platelets from mice fed the high choline diet (p=0.0002), and was greatest at submaximal levels of agonist”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Analyses of fecal samples revealed significant increases in choline levels following FMC or IMC administration, which before addition of the inhibitor were extremely low (Supplementary Figures 9,10). Importantly, no significant effects on plasma choline levels were observed”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FMC was also more potent than IMC against our polymicrobial, human fecal cultures (EC50=7.9 nM and 1.6 μM, respectively; Table 1).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“DMB significantly reduced both TMAO levels (p<0.0001) and stimulus-dependent (ADP) platelet aggregation (p=0.003) in PRP recovered from choline-supplemented mice”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“provision of DMB attenuated the choline diet-induced rise in TMAO and rate of clot formation (p=0.002; Figure 1b,c).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > DMB, a microbial choline TMA lyase inhibitor, attenuates choline diet-enhanced platelet responsiveness and in vivo rate of thrombus formation
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“within the large intestine (cecum and colon), the anatomic location where the majority of choline TMA lyase harboring commensals reside49, we observed the selective accumulation of each inhibitor to the millimolar level (2–6 mM), virtually complete elimination in detectable luminal TMA (product), and a similar marked increase in intestinal microbial choline (substrate) levels”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > IMC and FMC are preferentially sequestered within gut microbes
What the sources say
- Not checked yetcites [49] Koeth, R. A. et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of l-carnitine to TMAO. Cell Metab. 20, 799–812 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results confirmed complete suppression of choline diet-enhanced TMAO generation and accompanying enhancement in ADP-dependent platelet aggregation response with provision of either FMC (p=0.0001) or IMC (p=0.001; Figure 4a).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of gut microbial choline TMA lyase activity suppresses choline diet-enhanced platelet aggregation and in vivo rate of thrombus formation without increased bleeding time
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“both FMC and IMC showed dose-dependent suppression in both TMA production (EC50=4.5 and 31 mg/kg, respectively; Supplementary Figure 8) and systemic TMAO levels, with FMC demonstrating potency an order of magnitude greater than IMC (EC50=3.4 and 45 mg/kg, respectively; Table 1, Figure 3a right).”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FMC and IMC were detectable at low (μM) levels only for the first few hours in plasma, but their halomethylbetaine oxidation products, fluoromethylbetaine (FMB) and iodomethylbetaine (IMB), were ~10-fold more abundant, reaching their peak level 2 hours post-gavage”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“resveratrol was largely ineffective in each of the screening assays employed (Figure 1e) and showed no effect on plasma TMAO levels in vivo when administered to mice on a choline-supplemented diet (p=0.91; data not shown)”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
What the sources say
- Not checked yetcites [43] Chen, M. L. et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio 7, e02210–e02215 (2016).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of halomethylbetaines in all intestinal segments were significantly lower than their halomethylcholine counterparts, and there was no significant effect on gut luminal betaine or TMAO levels”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > IMC and FMC are preferentially sequestered within gut microbes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Provision of a high-choline diet was associated with both significant increases (e.g. Dehalobacterium and Adlercreutzia) and reductions (e.g. Bifidobacterium) in the proportions of several genera, which were each also significantly associated with both TMAO levels and time to vessel occlusion; moreover, these shifts in proportions were reversed with the addition of IMC”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of microbial choline TMA lyase activity shifts intestinal microbial communities
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Principal Coordinates Analysis of microbial taxa revealed distinct clusters, indicating both dietary choline supplementation and IMC exposure each induced significant (p=0.001) rearrangements in microbial composition”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of microbial choline TMA lyase activity shifts intestinal microbial communities
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neither FMC (p=0.85) nor IMC (p=0.73) led to a prolongation in occlusion time beyond that observed with normal chow.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of gut microbial choline TMA lyase activity suppresses choline diet-enhanced platelet aggregation and in vivo rate of thrombus formation without increased bleeding time
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“provision of either FMC (p<0.0001) or IMC (p<0.0001) completely blocked choline-supplemented diet-induced increases in both plasma TMAO and in vivo rate of clot formation”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of gut microbial choline TMA lyase activity suppresses choline diet-enhanced platelet aggregation and in vivo rate of thrombus formation without increased bleeding time
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“reversing choline diet-induced increases in platelet responses to agonists and thrombus formation in vivo.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Provision of IMC reversed choline diet-dependent increases in both TMAO levels and platelet adherence to collagen matrix to levels observed in chow-fed mice”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Inhibition of gut microbial choline TMA lyase activity suppresses choline diet-enhanced platelet aggregation and in vivo rate of thrombus formation without increased bleeding time
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is also notable that both IMC and FMC induced a shift in mouse cecal microbiota composition, particularly on a choline-supplemented diet, reversing choline-induced changes in the proportions of certain taxa.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“by inhibiting gut microbial production of TMA, we suppressed plasma TMAO levels for prolonged periods with limited systemic exposure of the drugs within the host”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“even if the inhibitors are non-lethal to cultured bacteria in nutrient-rich broths and fail to demonstrate reduction in microbial fitness with prolonged exposures.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“enhances both platelet responsiveness and in vivo thrombosis potential in animal models”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a link between dietary phosphatidylcholine, a nutrient common in a Western diet, gut microbiota-dependent generation of the metabolite trimethylamine N-oxide (TMAO), and cardiovascular disease (CVD) pathogenesis, was first described7.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Introduction
What the sources say
- Not checked yetcites [7] Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“recent studies reveal TMAO alters calcium signaling in platelets, enhancing responsiveness and in vivo thrombosis potential in animal models15.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Introduction
What the sources say
- Not checked yetcites [15] Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111–124 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Use of antiplatelet agents has become a cornerstone for the treatment of CVD because of substantial reduction in CVD events and mortality37,38. However, more widespread use of antiplatelet agents has been limited by the increased risk of bleeding, which also leads to nonadherence39–41.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Introduction
What the sources say
- Not checked yetcites [37] Bobadilla, R. V. Acute coronary syndrome: focus on antiplatelet therapy. Crit. Care Nurse 36, 15–27 (2016). source
- Not checked yetcites [38] Levine, G. N. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Thorac. Cardiovasc. Surg. 152, 1243–1275 (2016). source
- Not checked yetcites [39] Jennings, L. K. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb. Haemost. 102, 248–257 (2009). source
- Not checked yetcites [40] Manchikanti, L. et al. Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy. Pain. Physician 16, SE261–SE318 (2013).
- Not checked yetcites [41] Cohen, M. Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Mayo Clin. Proc. 84, 149–160 (2009). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“When given to atherosclerosis-prone ApoE−/− mice on a choline-supplemented diet, plasma TMAO levels were significantly lowered, and concurrently, macrophage cholesterol accumulation, foam cell formation and atherosclerotic lesion development were attenuated35.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Introduction
What the sources say
- Not checked yetcites [35] Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Herein we show that a mechanism-based non-lethal inhibitor of the gut microbial TMAO pathway designed to selectively accumulate within the gut microbial compartment, can serve as a new therapeutic approach for attenuating thrombosis while simultaneously limiting systemic exposure in the host.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mouse models used for platelet function and thrombosis predict human clinical effects of the inhibitors.
In the paper
“We recently reported the use of a natural product, 3,3-dimethyl-1-butanol (DMB), as a tool drug that inhibits microbial choline TMA lyase activity in vitro and in vivo35.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Introduction
What the sources say
- Not checked yetcites [35] Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“both IMC and FMC display numerous characteristics consistent with a covalent mode of inhibition (time-dependent, irreversible, and non-competitive inhibition)”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > Design and development of potent, mechanism-based, non-lethal microbial CutC/D inhibitors
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Kinetic analyses demonstrate that IMC and FMC are non-competitive, time-dependent and irreversible, hallmarks of mechanism-based inhibitors.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“inhibition in microbial TMAO generation would not hypothetically suppress platelet function “below normal” and thus heighten bleeding risks.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The present studies suggest development of poorly absorbed suicide substrate inhibitors of gut microbial catabolic pathways mechanistically linked with disease pathogenesis deserves further investigation as a potentially generalizable approach to achieve therapeutic outcomes in the host.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Rests on an assumption: The mouse models used in these studies predict human TMAO metabolism, thrombosis, and therapeutic response.
- Rests on an assumption: The inhibitor-induced changes in mouse cecal microbiota composition represent effects on the human gut microbiome.
- Rests on an assumption: The absence of systemic toxicity and bleeding effects in mice predicts safety in humans.
In the paper
“fluorine substitution can confer properties beneficial to the chemistry of suicide substrate inhibitors and their potential use as pharmaceuticals56.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
What the sources say
- Not checked yetcites [56] Clarke, D. D. Fluoroacetate and fluorocitrate: mechanism of action. Neurochem. Res. 16, 1055–1058 (1991). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators were not blinded to mouse group allocation during the performance of animal husbandry requirements for experiments.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators performing quantitative analyses of endpoints (e.g., plasma, urine, or fecal metabolite levels) were blinded to group allocation with samples labeled by code only.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“many drugs induce shifts in microbial community composition57,58.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
What the sources say
- Not checked yetcites [57] Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016). source
- Not checked yetcites [58] Rogers, M. A. M. & Aronoff, D. M. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin. Microbiol. Infect. 22, 178.e1–178.e9 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In a recent examination of over 1,000 clinically used drugs and their impact on a broad selection of human gut commensals, nearly a quarter demonstrated antibiotic-like side effects59.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
What the sources say
- Not checked yetcites [59] Maier, L. et al. Extensive impact of nonantibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“And in a recent elegant study with metformin, a shift in microbial community structure was suggested to contribute in part to its observed beneficial metabolic effects60.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
What the sources say
- Not checked yetcites [60] Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results suggest that inhibition in microbial choline utilization will not only suppress TMA/TMAO generation, but also may help enhance choline bioavailability for the host.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Results from all animals in a given experiment were included in the analyses.”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The mouse models used for platelet function and thrombosis predict human clinical effects of the inhibitors.
“Herein we show that a mechanism-based non-lethal inhibitor of the gut microbial TMAO pathway designed to selectively accumulate within the gut microbial compartment, can serve as a new therapeutic approach for attenuating thrombosis while simultaneously limiting systemic exposure in the host.”
The paper relies on this without support.
The CutC/D enzymes and microbial cultures used in screening represent the diversity of human gut microbial choline TMA lyases.
“We developed a tiered screening assay system to test for broad efficacy among phylogenetically diverse commensal bacteria that contain CutC/D and robust choline TMA lyase activity.”
The paper relies on this without support.
The absence of toxicity in mice over the studied exposure periods predicts safety in humans.
“No signs of toxicity were observed in mice following chronic exposure to wholly effective doses of FMC (10 mg/kg) or IMC (100 mg/kg)”
The paper relies on this without support.
The mouse models used in these studies predict human TMAO metabolism, thrombosis, and therapeutic response.
“These studies suggest a new potential target for the treatment of subjects at risk for thrombotic complications and cardiovascular disease.”
The paper relies on this without support.
The inhibitor-induced changes in mouse cecal microbiota composition represent effects on the human gut microbiome.
“It is also notable that both IMC and FMC induced a shift in mouse cecal microbiota composition”
The paper relies on this without support.
The absence of systemic toxicity and bleeding effects in mice predicts safety in humans.
“Importantly, no evidence of systemic toxicity was observed and our treatment did not adversely affect bleeding potential”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has also been shown to promote platelet reactivity and thrombosis potential14, 83–85, vascular inflammation and inflammasome activation86–88, heightened heart failure89–91 and CKD92–95 related phenotypes in animal models (Figure 2).”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [85]
In the citing paper
“Thus, decreasing systemic levels of TMAO has become a rational potential therapeutic strategy for decreasing risks for the development and progression of atherosclerotic heart disease.8,[13][14][15]”
From Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women (2019) · cites this paper as [13]
In the citing paper
“Interestingly, owing to their highly polar nature, FMC and related halomethylcholines were shown to be poorly absorbed into the host, limiting systemic exposure and thus chances of side effects.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [85]
In the citing paper
“The choline TMA lyase suicide substrate inhibitor fluoromethylcholine (FMC) was shown to be over 10,000 fold more potent an inhibitor of cutC than DMB, and markedly blocks microbial choline catabolism85.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [85]
In the citing paper
“This then induces expression of the entire choline utilization gene cluster, including both cutC and the microbial choline transporter.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [85]
In the citing paper
“In addition, cutC inhibition by FMC and iodomethylcholine (IMC) was shown to result in microbial cytosolic choline elevation, which appears to be sensed as an abundant fuel source by the microbe.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [85]
In the citing paper
“As intestinal luminal choline is depleted, microbial community TMA production is globally inhibited, even from neighboring community members who might otherwise not be potently inhibited85.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Results > FMC and IMC suppress host TMA and TMAO levels for sustained periods of time with limited systemic exposure and without observed toxicity
“liver function tests (ALT, AST, BUN)”
§ Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential > Methods > In vivo toxicity studies
“Plasma was analyzed for liver (ALT, AST) and kidney function (BUN) using a Roche Cobas C 311 analyzer”
Citations
Cites
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Self-citationIntestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Self-citationIndigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Self-citationHuman nutrition, the gut microbiome and the immune system
Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., & Gordon, J. I. (2011) · Nature · doi:10.1038/nature10213 · Cited by 2,588
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
Self-citationMechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926
Extensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Signals from the gut microbiota to distant organs in physiology and disease
Schroeder, B. O., & Bäckhed, F. (2016) · Nature Medicine · doi:10.1038/nm.4185 · Cited by 1,409
Cited by
Sorted by citations
Items 101–200 of 559
Ghaffari, S., Abbasi, A., Somi, M. H., Moaddab, S. Y., Nikniaz, L., Kafil, H. S., & Leylabadlo, H. E. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2045894 · Cited by 74
Unraveling the Role of the Human Gut Microbiome in Health and Diseases
Khalil, M., Ciaula, A. D., Mahdi, L., Jaber, N., Palo, D. M. D., Graziani, A., Baffy, G., & Portincasa, P. (2024) · Microorganisms · doi:10.3390/microorganisms12112333 · Cited by 100
Smoking-induced microbial dysbiosis in health and disease
Shapiro, H., Goldenberg, K., Ratiner, K., & Elinav, E. (2022) · Clinical Science · doi:10.1042/cs20220175 · Cited by 77
Gut microbiome and cardiovascular disease
Zhao, Y., & Wang, Z. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000720 · Cited by 70
Self-citationZhang, Y., Xu, J., Wang, X., Ren, X., & Liu, Y. (2019) · BMC Genomics · doi:10.1186/s12864-019-6251-7 · Cited by 63
Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes
Croyal, M., Saulnier, P., Aguesse, A., Gand, E., Ragot, S., Roussel, R., Halimi, J., Ducrocq, G., Cariou, B., Montaigne, D., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa188 · Cited by 73
Digesting the complex metabolic effects of diet on the host and microbiome
Carmody, R. N., Varady, K. A., & Turnbaugh, P. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.032 · Cited by 76
The Microbiota Promotes Arterial Thrombosis in Low-Density Lipoprotein Receptor-Deficient Mice
Kiouptsi, K., Jäckel, S., Pontarollo, G., Grill, A., Kuijpers, M. J. E., Wilms, E., Weber, C., Sommer, F., Nagy, M., Neideck, C., et al. (2019) · mBio · doi:10.1128/mbio.02298-19 · Cited by 70
Zou, B., Li, J., Ma, R., Cheng, X.-Y., Ma, R.-Y., Zhou, T.-Y., Wu, Z., Yao, Y., & Li, J. (2023) · Aging and Disease · doi:10.14336/ad.2022.1127 · Cited by 76
Ilyas, A., Wijayasinghe, Y. S., Khan, I., Samaloty, N. M. E., Adnan, M., Dar, T. A., Poddar, N. K., Singh, L. R., Sharma, H., & Khan, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.964624 · Cited by 73
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality
Molinaro, A., Nemet, I., Lassen, P. B., Chakaroun, R., Nielsen, T., Aron‐Wisnewsky, J., Bergh, P., Li, L., Henricsson, M., Køber, L., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.008 · Cited by 73
Self-citationOrman, M., Bodea, S., Funk, M. A., Campo, A. M.-D., Bollenbach, M., Drennan, C. L., & Balskus, E. P. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04883 · Cited by 64
Shih, D. M., Zhu, W., Schugar, R. C., Meng, Y., Jia, X., Miikeda, A., Wang, Z., Zieger, M., Lee, R., Graham, M., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312592 · Cited by 67
Self-citationRole of the Gut Microbiota in Stroke Pathogenesis and Potential Therapeutic Implications
Yamashiro, K., Kurita, N., Urabe, T., & Hattori, N. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000516398 · Cited by 72
Targeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis
Jing, L., Zhang, H., Xiang, Q., Shen, L., Guo, X., Zhai, C., & Hu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.864600 · Cited by 69
The emerging role of gut microbial metabolism on cardiovascular disease
Kasahara, K., & Rey, F. E. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.09.007 · Cited by 59
Mahdavi‐Roshan, M., Salari, A., Kheirkhah, J., & Ghorbani, Z. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.09.006 · Cited by 63
Tousoulis, D., Guzik, T. J., Padró, T., Duncker, D. J., Luca, G. D., Eringa, E. C., Vavlukis, M., Antonopoulos, A. S., Katsimichas, T., Cenko, E., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac057 · Cited by 67
Gut microbiota: a non-target victim of pesticide-induced toxicity
Sharma, T., Natesh, N. S., Pothuraju, R., Batra, S. K., & Rachagani, S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2187578 · Cited by 68
Treatments of trimethylaminuria: where we are and where we might be heading
Schmidt, A. C., & Leroux, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.026 · Cited by 55
Elevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy
Liu, W., Wang, C., Xia, Y., Xia, W. T., Liu, G., Ren, C., Gu, Y., Li, X., & Lu, P. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01610-9 · Cited by 66
The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis
Wang, Z., Hazen, J. E., Jia, X., Org, E., Zhao, Y., Osborn, L. J., Nimer, N. A., Buffa, J. A., Culley, M. K., Krajcik, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413477 · Cited by 52
Self-citationVia, A. D., Gargari, G., Taverniti, V., Rondini, G., Velardi, I., Gambaro, V., Visconti, G. L., Vitis, V. D., Gardana, C., Ragg, E. M., et al. (2019) · Nutrients · doi:10.3390/nu12010062 · Cited by 64
Liang, X., Zhang, Z., Lv, Y., Tong, L., Liu, T., Yi, H., Zhou, X., Yu, Z., Tian, X., Cui, Q., et al. (2020) · Nutrition · doi:10.1016/j.nut.2020.110941 · Cited by 62
Circulating trimethylamine N-oxide levels following fish or seafood consumption
Wang, Z., Tang, W. H. W., O’Connell, T. F., Garcia, E., Jeyarajah, E. J., Li, X. S., Jia, X., Weeks, T. L., & Hazen, S. L. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02803-4 · Cited by 63
Self-citationSequence meets function—microbiota and cardiovascular disease
Kim, M., Huda, M. N., & Bennett, B. J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab030 · Cited by 62
Tacconi, E., Palma, G., Biase, D. D., Luciano, A., Barbieri, M., de Nigris, F., & Bruzzese, F. (2023) · Nutrients · doi:10.3390/nu15030563 · Cited by 62
Gut microbial metabolites and its impact on human health
Rahman, S. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0809 · Cited by 70
Tan, C., Wang, H., Gao, X., Xu, R., Zeng, X., Cui, Z., Zhu, J., Wu, Q., Xia, G., Zhou, H., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00029 · Cited by 55
Relationship Between the Gut Microbiome and Systemic Chemotherapy
Ervin, S. M., Ramanan, S. V., & Bhatt, A. P. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06119-3 · Cited by 62
Wu, W., Panyod, S., Liu, P., Chen, C., Kao, H., Chuang, H.-L., Chen, Y., Zou, H.-B., Kuo, H., Kuo, C.-H., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00912-y · Cited by 58
Xie, Y., Hu, X.-F., Li, S., Qiu, Y., Cao, R., Xu, C., Lu, C., Wang, Z., & Yang, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106161 · Cited by 62
Self-citationNovel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A. M., & Shaw, J. A. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 62
The Gut Microbial Endocrine Organ in Type 2 Diabetes
Massey, W. J., & Brown, J. M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa235 · Cited by 61
Self-citationTrimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD
Li, X., Hong, J. W., Wang, Y., Pei, M., Wang, L., & Gong, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.733507 · Cited by 59
Helsley, R. N., Miyata, T., Kadam, A., Varadharajan, V., Sangwan, N., Huang, E., Banerjee, R., Brown, A. L., Fung, K. K., Massey, W. J., et al. (2022) · eLife · doi:10.7554/elife.76554 · Cited by 57
Self-citationImmune Mechanisms of Plaque Instability
Gerhardt, T., Haghikia, A., Stapmanns, P., & Leistner, D. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.797046 · Cited by 66
Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases
Mutalub, Y. B., Abdulwahab, M., Mohammed, A., Yahkub, A. M., Al-Mhanna, S. B., Yusof, W., Tang, S. P., Rasool, A. H. G., & Mokhtar, S. S. (2022) · Foods · doi:10.3390/foods11172575 · Cited by 64
The Mediterranean Diet, Its Microbiome Connections, and Cardiovascular Health: A Narrative Review
Abrignani, V., Salvo, A., Pacinella, G., & Tuttolomondo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094942 · Cited by 97
Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities
Hul, M. V., Neyrinck, A. M., Everard, A., Abot, A., Bindels, L. B., Delzenne, N. M., Knauf, C., & Cani, P. D. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00045-23 · Cited by 60
Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases
Xu, J., & Yang, Y. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1936379 · Cited by 61
Gut Microbial-Derived Metabolites as Immune Modulators of T Helper 17 and Regulatory T Cells
Calvo‐Barreiro, L., Zhang, L., Abdel‐Rahman, S. A., Naik, S. P., & Gabr, M. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021806 · Cited by 62
Mars, R. A. T., Frith, M., & Kashyap, P. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.058 · Cited by 53
Yang, J. J., Shu, X., Herrington, D. M., Moore, S. C., Meyer, K. A., Ose, J., Menni, C., Palmer, N. D., Eliassen, A. H., Harada, S., et al. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa430 · Cited by 54
A Gut-Restricted Lithocholic Acid Analog as an Inhibitor of Gut Bacterial Bile Salt Hydrolases
Adhikari, A. A., Ramachandran, D., Chaudhari, S. N., Powell, C. E., Li, W., McCurry, M. D., Banks, A. S., & Devlin, A. S. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00192 · Cited by 56
Mediterranean diet and mitochondria: New findings
Pollicino, F., Veronese, N., Dominguez, L. J., & Barbagallo, M. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112165 · Cited by 59
Local barriers configure systemic communications between the host and microbiota
Lu, Q., & Stappenbeck, T. S. (2022) · Science · doi:10.1126/science.abo2366 · Cited by 56
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment
Chen, H., Gong, J.-Y., Xing, K., Liu, M.-Z., Ren, H., & Luo, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.742394 · Cited by 59
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease
Hage, R. E., Al-Arawe, N., & Hinterseher, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032399 · Cited by 56
Wei, D., Li, Y., Che, M., Li, C., Wu, Q., & Sun, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04412-0 · Cited by 41
The Gut Microbial Metabolite Trimethylamine N-oxide, Incident CKD, and Kidney Function Decline
Wang, M., Tang, W. H. W., Li, X. S., Otto, M. C. D. O., Lee, Y., Lemaître, R. N., Fretts, A. M., Nemet, I., Sotoodehnia, N., Sitlani, C. M., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000344 · Cited by 60
Self-citationGessner, A., di Giuseppe, R., Koch, M., Fromm, M. F., Lieb, W., & Maas, R. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1146 · Cited by 51
Kuka, J., Ozola, M., Makrecka‐Kuka, M., Liepinsh, E., Grīnberga, S., Sevostjanovs, E., Vilks, K., Liepinsh, E., & Dambrova, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-71470-4 · Cited by 54
Ahmed, S., & Spence, J. D. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00378-z · Cited by 51
The human microbiota is associated with cardiometabolic risk across the epidemiologic transition
Fei, N., Bernabé, B. P., Lie, L., Baghdan, D., Bedu-Addo, K., Plange‐Rhule, J., Forrester, T., Lambert, E. V., Bovet, P., Gottel, N., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215262 · Cited by 52
Implications of Gut Microbiota in Complex Human Diseases
Yu, D., Meng, X., de Vos, W. M., Wu, H., Fang, X., & Maiti, A. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312661 · Cited by 51
Xiao, X., Cheng, Y., Fu, J., Lu, Z., Wang, F., Jin, M., Zong, X., & Wang, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6634821 · Cited by 51
Small Molecule Metabolites at the Host–Microbiota Interface
Bishai, J. D., & Palm, N. W. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100528 · Cited by 50
Gut microbiota dependant trimethylamine N-oxide and hypertension
Mutengo, K. H., Masenga, S. K., Mweemba, A., Mutale, W., & Kirabo, A. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1075641 · Cited by 53
Iliou, A., Mikros, E., Karaman, İ., Elliott, F., Griffin, J. L., Tzoulaki, I., & Elliott, P. (2021) · Heart · doi:10.1136/heartjnl-2019-315615 · Cited by 47
Gut microbial metabolism in Alzheimer's disease and related dementias
Kang, J. W., Vemuganti, V., Kuehn, J. F., Ulland, T. K., Rey, F. E., & Bendlin, B. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00470 · Cited by 53
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value
Li, X., Fan, Z., Cui, J., Li, D., Lu, J., Cui, X., Xie, L., Wu, Y., Lin, Q., & Li, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.817396 · Cited by 47
Gut microbiota and their metabolites in cardiovascular disease
Jansen, V. L. B. I., Gerdes, V. E. A., Middeldorp, S., & van Mens, T. E. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101492 · Cited by 50
Gut Microbiome in Chronic Coronary Syndrome Patients
Sawicka, E., Bondarczuk, K., Bauer, W., Niemira, M., Szalkowska, A., Raczkowska, J., Kwaśniewski, M., Tarasiuk, E., Dubatówka, M., Łapińska, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215074 · Cited by 46
Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation
Iglesias‐Carres, L., Hughes, M. D., Steele, C. N., Ponder, M. A., Davy, K. P., & Neilson, A. P. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108600 · Cited by 43
Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases
He, S., Jiang, H., Zhuo, C., & Jiang, W. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09656-z · Cited by 46
Association of Gut Microbiota-Dependent Metabolite Trimethylamine N-Oxide with First Ischemic Stroke
Sun, T., Zhang, Y., Yin, J., Peng, X., Zhou, L., Huang, S., Wen, Y., Cao, B., Chen, L., Li, X., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.55962 · Cited by 44
Wang, H., Zhang, H., & Su, Y. (2022) · Animals · doi:10.3390/ani12131677 · Cited by 48
Feng, R., Tian, Z., Mao, R., Ma, R., Luo, W., Zhao, M., Li, X., Liu, Y., Huang, K., Xiang, L., et al. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad098 · Cited by 44
Targeting the human gut microbiome with small-molecule inhibitors
Woo, A. Y. M., Aguilar Ramos, M. A., Narayan, R., Richards-Corke, K. C., Wang, M. L., Sandoval-Espinola, W. J., & Balskus, E. P. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00471-4 · Cited by 42
Effects of Smoking and Smoking Cessation on the Intestinal Microbiota
Sublette, M. G., Cross, T.-W., Korcarz, C. E., Hansen, K. M., Murga-Garrido, S. M., Hazen, S. L., Wang, Z., Oguss, M. K., Rey, F. E., & Stein, J. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092963 · Cited by 53
Self-citationSi, Y., Wei, W., Chen, X., Xie, X., Guo, T., Sasaki, Y., Zhang, Y.-B., Wang, L., Zhang, F., & Feng, S. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2021.2019283 · Cited by 47
Wang, Y., Uffelman, C. N., Bergia, R. E., Clark, C. M., Reed, J. B., Cross, T.-W., Lindemann, S. R., Tang, M., & Campbell, W. W. (2022) · Advances in Nutrition · doi:10.1016/j.advnut.2022.10.005 · Cited by 44
Self-citationThe Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications
Zhang, S., Zhou, J., Wu, W., Zhu, Y. S., & Liu, X. (2022) · Aging and Disease · doi:10.14336/ad.2022.0817 · Cited by 43
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 49
Antibiotic Treatment Protocols and Germ-Free Mouse Models in Vascular Research
Bayer, F., Ascher, S., Pontarollo, G., & Reinhardt, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02174 · Cited by 44
Microbiota in cerebrovascular disease: A key player and future therapeutic target
Tonomura, S., Ihara, M., & Friedland, R. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20918031 · Cited by 41
A Review on the Health Effects of Pesticides Based on Host Gut Microbiome and Metabolomics
Zhou, M., & Zhao, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.632955 · Cited by 43
Yang, S., Li, D., Yu, Z., Li, Y., & Wu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709629 · Cited by 40
Krueger, E. S., Lloyd, T. S., & Tessem, J. S. (2021) · Nutrients · doi:10.3390/nu13082873 · Cited by 41
Dong, F., Jiang, S., Tang, C., Wang, X., Ren, X., Wei, Q., Tian, J., Hu, W., Guo, J. Z., Fu, X., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.11.010 · Cited by 44
Self-citationChen, C., Leu, H., Wang, S., Tsai, S., Chou, R., Lu, Y., Tsai, Y., Kuo, C., Huang, P., Chen, J., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0115 · Cited by 41
Gut Microbiota Involvement in Ventricular Remodeling Post–Myocardial Infarction
McMillan, A., & Hazen, S. L. (2019) · Circulation · doi:10.1161/circulationaha.118.037384 · Cited by 39
Self-citationZhou, Y., Han, W., Feng, Y., Wang, Y., Sun, T., & Xu, J. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5661 · Cited by 41
The gut–immune axis during hypertension and cardiovascular diseases
Dinakis, E., O’Donnell, J. A., & Marques, F. Z. (2024) · Acta Physiologica · doi:10.1111/apha.14193 · Cited by 49
Cazac, G.-D., Lăcătușu, C.-M., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2022) · Life · doi:10.3390/life12081189 · Cited by 41
Trimethylamine-N-oxide and cerebral stroke risk: A review
Dolkar, P., Deyang, T., Anand, N., Rathipriya, A. G., Hediyal, T. A., Vichitra, C., Krishnamoorthy, N. K., Gorantla, V. R., Bishir, M., Rashan, L. J., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106423 · Cited by 46
Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis
Jang, J. W., Capaldi, E., Smith, T. L., Verma, P., Varga, J., & Ho, K. J. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00895-8 · Cited by 48
Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease
Zhao, Y., & Wang, Z. (2020) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm.2020.01.01 · Cited by 42
Self-citationGut Microbiota and Cardiovascular Diseases
Anselmi, G., Gagliardi, L., Egidi, G., Leone, S., Gasbarrini, A., Miggiano, G. A. D., & Galiuto, L. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000327 · Cited by 37
Li, Q., Gao, B. X., Bateer, S., He, Q., Zhang, R., Meng, X., Naiheng, Z., Li, M., & Li, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.651926 · Cited by 40
Sharma, V. K., Tan, B. Y., & Paliwal, P. R. (2019) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_483_19 · Cited by 38
The intestinal microbiome potentially affects thrombin generation in human subjects
Mohammed, Y., Kootte, R. S., Kopatz, W. F., Borchers, C. H., Buller, H. R., Versteeg, H. H., Nieuwdorp, M., & van Mens, T. E. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14699 · Cited by 36
Targeting the gut microbial metabolic pathway with small molecules decreases uremic toxin production
Wang, Y., Li, J., Chen, C., Lu, J., Yu, J., Xu, X., Peng, Y., Zhang, S., Jiang, S., Guo, J., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1823800 · Cited by 41
Iglesias‐Carres, L., Essenmacher, L. A., Racine, K. C., & Neilson, A. P. (2021) · Nutrients · doi:10.3390/nu13051466 · Cited by 34
Trimethylamine oxide: a potential target for heart failure therapy
Lv, S., Wang, Y., Zhang, W., & Shang, H. (2021) · Heart · doi:10.1136/heartjnl-2021-320054 · Cited by 35
Hu, X., Fan, Y., Li, H., Zhou, R., Zhao, X., Sun, Y., & Zhang, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.766739 · Cited by 36
Wilcox, J. D., Skye, S. M., Graham, B., Zabell, A., Li, X. S., Li, L., Shelkay, S., Fu, X., Neale, S., OʼLaughlin, C., et al. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.016 · Cited by 44
Self-citationAlexander, E. M., Kreitler, D. F., Guidolin, V., Hurben, A. K., Drake, E. J., Villalta, P. W., Balbo, S., Gulick, A. M., & Aldrich, C. C. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00326 · Cited by 39
He, M., Tan, C. P., Xu, Y., & Liu, Y. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109812 · Cited by 37
Metadata
- Authors
- Roberts, A. B., Gu, X., Buffa, J. A., Hurd, A. G., Wang, Z., Zhu, W., Gupta, N., Skye, S. M., Cody, D. B., Levison, B. S., Barrington, W. T., Russell, M. W., Reed, J. M., Duzan, A., Lang, J. M., Fu, X., Li, L., Myers, A. J., Rachakonda, S., DiDonato, J. A., Brown, J. M., Gogonea, V., Lusis, A. J., Garcia-Garcia, J. C., & Hazen, S. L.
- Affiliations
- Cleveland Clinic (US)
- Procter & Gamble (United States) (US)
- University of California, Los Angeles (US)
- Cleveland State University (US)
- Corresponding author
- Hazen, Stanley L.
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-08-06
- Volume
- 24
- Issue
- 9
- Pages
- 1407-1417
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6129214
- OpenAlex
- W2884566703
- Cited by
- 552
- References
- 62
- Citations by year
- 2026: 56 · 2025: 66 · 2024: 54 · 2023: 77 · 2022: 80 · 2021: 76 · 2020: 77 · 2019: 47 · 2018: 18
- FWCI
- 19.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Cleveland Clinic
- National Institutes of Health (5t32dk007470-35)
- National Institute on Alcohol Abuse and Alcoholism (P50AA024333)
- National Heart, Lung, and Blood Institute (P01HL030568, R01HL126827, R01HL103866, R01HL122283, P01HL028481)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK106000, T32-DK 007470)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- trimethylamine N-oxide, gut microbiota, thrombosis, platelet response, mechanism-based inhibitors, irreversible inhibitors, atherothrombosis, Western diet, thrombus formation
- MeSH terms
- Gastrointestinal Microbiome, Hexanols, Animals, Bacteria, Choline, Diet, Mice, Inbred C57BL, Oxidoreductases, N-Demethylating, Platelet Aggregation, Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
